National Academies Press: OpenBook

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)

Chapter: Appendix 11: Human Paillomavirus

« Previous: Appendix 10: Histoplasma capsulatum
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

APPENDIX 11
Human Papillomavirus

Human papillomavirus (HPV) infects stratified squamous, metaplastic squamous, and columnar epithelial cells. The majority of human papillomavirus cells are self-limited, but there is now a clear correlation between malignant tumors and the development of a subset of infections that involve oncogenic viruses. Specific types of HPV tend to infect different types of epithelia and produce different clinical and pathogenic manifestations. The two distinct types of cells are mucosal HPV infection and cutaneous HPV infection.

Genital tract HPV is thought to be currently the most common sexually transmitted viral infection in the United States. Genital warts occur on the vulva, vagina, cervix, penis, and anus. In addition to being a common STD, genital HPV infection is of considerable importance in the pathogenesis role of epithelial cancers of the female and male genital tracts.

DISEASE BURDEN

Epidemiology

For the purposes of the calculations in this report, the committee estimated that there are 1 million new infections of human papillomavirus (HPV) each year in the United States in males and females between the ages of 15 and 29 years of age. New infections are equally divided between males and females.

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Disease Scenarios

For the purposes of the calculation in this report, the committee assumed that approximately half of women with HPV infection experience a 3-month episode of limited or severe genital warts and the other half experience recurrences of limited or severe genital warts. Health utility indices (HUI) associated with those episodes range from .85 to .95. It was assumed that 10% of women with HPV infections develop cervical dysplasia due to the infection. It was also assumed that cancers that develop secondary to HPV infection occur with an average lag of 25 years from time of infection. Cervical cancers were separately described as carcinoma in situ, locally invasive at diagnosis, and advanced at diagnosis. Treatment phases and follow-up phases are included, with HUI and duration of that state ranging from 4 months of treatment at an HUI of .8 to 16 years of life spent at an HUI of .9.

Sequelae of HPV infection of men was assumed to parallel to a great degree that in women: several scenarios of genital warts and penile cancers. HUI and duration of time in the specific disease states show the same ranges as for women. Table A11–1 shows the disease states for both men and women.

COST INCURRED BY DISEASE

Table A11–2 summarizes the health care costs incurred by HPV infections. For the purposes of the calculations in this report, it was assumed that women with genital warts incur costs associated with physician visits and diagnostics. More severe cases were assumed to involve more frequent physician visits. It was assumed that approximately half of women with mild recurrent warts and all of the women with extensive recurrent warts visit a physician four times per year. It was assumed that women with cervical dysplasia incur costs associated with specialist visits, diagnostics, and follow-up visits for 1.5 years.

It was assumed that cervical carcinoma in situ was associated with multiple visits, advanced diagnostics, and ambulatory surgery during the treatment phase. During the 2-year follow-up, it was assumed that all patients receive 3 follow-up visits; and diagnostics per year. Treatment for locally invasive cervical cancer was assumed to be associated with physician visits, diagnostics, hospitalization, including costs for surgeons/anesthesiologists; and radiation therapy. The 2-year follow-up phase was assumed to include quarterly physician and diagnostic evaluation. Advanced cervical cancer was associated with similar treatment costs as for locally invasive cancer, but with increased physician visits during both the treatment phase and the follow-up phase.

Treatment patterns for acute and chronic (recurring genital warts and penile cancers) sequelae of HPV infection in men were assumed to be similar to that of treatment patterns in women.

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A11–1 Disease Scenarios for Women and Men for HPV Infection

 

No. of Cases

% of Cases

Committee HUI Values

Duration (years)

WOMEN

 

Genital warts, limited

237,500

47.5%

 

minor physical discomfort

 

0.95

0.2500 (3 months)

Genital warts, limited but recurring

237,500

47.5%

 

minor physical discomfort (2 recurrences per year for 10 years)

 

0.90

0.5000 (6 months/year)

Genital warts, extensive

12,500

2.5%

 

same physical discomfort

 

0.85

0.2500 (3 months)

Genital warts, extensive and recurring

12,500

2.5%

 

some physical discomfort (2 recurrences per year for 10 years)

 

0.85

0.5000 (6 months/year)

Cervical dysplasia

50,000

10.0%

0.97

1.5000 (18 months)

All Cancers: assume average 25-year lag from infection

Cervical cancer—carcinoma in situ

25,000

5.0%

 

treatment phase

 

0.80

0.3333 (4 months)

posttreatment phase (follow-up)

 

0.97

2.0000 (2 years)

Cervical cancer—locally invasive at diagnosis

5,000

1.0%

 

treatment phase (surgery, radiation, chemotherapy)

 

0.79

0.3333 (4 months)

posttreatment phase (follow-up)

 

0.90

16.7349 (years remaining)

Cervical cancer—advanced at diagnosis

2,500

0.5%

 

treatment phase (surgery, radiation, chemotherapy)

 

0.62

0.3333 (4 months)

posttreatment phase (follow-up and sequelae e.g., infertiity, sexual dysfunction, urinary dysfunction)

 

0.62

3.0000 (3 years)

premature death (by 3 years after diagnosis)

 

0.00

15.7265 (years lost)

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

 

No. of Cases

% of Cases

Committee HUI Values

Duration (years)

MEN

 

Genital warts, limited

237,500

47.5%

 

minor physical discomfort

 

0.90

0.2500 (3 months)

Genital warts, limited but recurring

237,500

47.5%

 

minor physical discomfort (2 recurrences per year for 10 years)

 

0.90

0.5000 (6 months/year)

Genital warts, extensive

12,500

2.5%

 

some physical discomfort

 

0.85

0.2500 (3 months)

Genital warts, extensive and recurring

12,500

2.5%

 

some physical discomfort (2 recurrences per year for 10 years)

 

0.85

0.5000 (6 months/year)

All Cancers: assume average 25-year lag from infection

Penile cancer—carcinoma in situ

25,000

5.0%

 

treatment phase

 

0.80

0.3333 (4 months)

post-treatment phase (follow-up)

 

0.97

2.0000 (2 years)

Penile cancer—locally invasive at diagnosis

5,000

1.0%

 

treatment phase (surgery, radiation, chemotherapy)

 

0.80

0.3333 (4 months)

post-treatment phase (follow-up)

 

0.90

16.7349 (years remaining)

Penile cancer—advanced at diagnosis

2,500

0.5%

 

treatment phase (surgery, radiation, chemotherapy)

 

0.62

0.3333 (4 months)

post-treatment phase (follow-up and sequelae e.g., infertility, sexual dysfunction, urinary dysfunction)

 

0.62

3.0000 (3 years)

premature death (by 3 years after diagnosis)

 

0.00

15.7265 (years lost)

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A11–2 Health Care Costs Associated with HPV Disease in Women and Men

 

% with Care

Cost per Unit

Units per Case

Form of Treatment

WOMEN

 

Genital warts, limited

 

minor physical discomfort

100%

$50

3

physician a

 

100%

$50

1

diagnostic a

Genital warts, limited but recurring

 

minor physical discomfort

50%

$50

4

physician a/year

2 recurrences per year for 10 years

50%

$50

1

diagnostic a

Genital warts, extensive

 

some physical discomfort

100%

$50

3

physician a

Genital warts, extensive and recurring

 

some physical discomfort

100%

$50

4

physician a/year

2 recurrences per year for 10 years

100%

$50

1

diagnostic a

Cervical dysplasia

 

treated precancerous condition

100%

$650

1

physician c plus diagnostic c

follow-up period

100%

$100

6

physician b

All Cancers: assume average 25-year lag from infection

Cervical cancer—carcinoma in situ

treatment phase

100%

$50

5

physician a

 

100%

$500

1

diagnostic c

100%

$1,000

1

ambulatory surgery

post-treatment phase (follow-up)

100%

$50

3

physician a/year

 

100%

$50

3

diagnostic a/year

Cervical cancer-locally invasive at diagnosis

treatment phase (surgery, radiation, chemotherapy)

100%

$100

2

physician b

 

100%

$500

2

diagnostic c

100%

$4,000

1

hospitalization

100%

$500

2

surgeons/anesthesiologist

100%

$5,000

1

radiation

follow-up

10%

$100

4

physician b/year

 

10%

$50

4

diagnostic a/year

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

 

% with Care

Cost per Unit

Units per Case

Form of Treatment

Cervical cancer—advanced at diagnosis

treatment phase (surgery, radiation, chemotherapy)

100%

$100

5

physician b

 

100%

$500

2

diagnostic c

100%

$4,000

1

hospitalization

100%

$5,000

1

radiation

100%

$500

2

surgeon/anesthesiologist

100%

$50

12

physician a

100%

$50

3

medication b

post-treatment phase (follow up and sequelae (e.g., infertility, sexual dysfunction, urinary dysfunction)

100%

$100

6

physician b/year

 

100%

$50

6

diagnostic a/year

MEN

 

Genital warts, limited

 

minor physical discomfort

100%

$50

1

physician a

minor physical discomfort; recurrences for 10 years

100%

$50

2

physician a/year

Genital warts, extensive

 

some physical discomfort

100%

$50

2

physician a

Genital warts, extensive and recurring

some physical discomfort

100%

$50

2

physician a

2 recurrences per year for 10 years

100%

$50

2

physician a/year

All Cancers: assume average 25-year lag from infection

Penile cancer—carcinoma in situ

treatment phase

100%

$50

1

physician a

 

50%

$1,000

1

ambulatory surgery

100%

$100

1

diagnostic b

50%

$4,000

1

hospitalization

100%

$500

2

surgeon/anaesthiologist

post-treatment phase (follow-up)

100%

$100

2

physician b/year

Penile cancer—locally invasive at diagnosis

treatment phase (surgery, radiation, chemotherapy)

100%

$100

1

physician b

 

100%

$4,000

1

hospitalization

100%

$500

2

surgeon/anesthesiologist

50%

$5,000

1

radiation

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

 

% with Care

Cost per Unit

Units per Case

Form of Treatment

Penile cancer—locally invasive at diagnosis

 

50%

$5,000

1

chemotherapy

post-treatment phase (follow-up)

100%

$50

1

physician a/year

Penile cancer—advanced at diagnosis

treatment phase (surgery, radiation, chemotherapy)

100%

$100

1

physician b

 

100%

$4,000

1

hospitalization

100%

$500

2

surgeon/anesthesiologist

50%

$5,000

1

radiation

50%

$5,000

1

chemotherapy

post-treatment phase (follow-up and sequelae (e.g., infertility, sexual dysfunction, urinary dysfunction)

100%

$100

6

physician b/year

VACCINE DEVELOPMENT

The committee assumed that it will take 7 years until licensure of a HPV vaccine and that $360 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

For the purposes of the calculations in this report, it is assumed that the target population for this vaccine male and female adolescents (age 12). It was assumed that 50% of the target population would utilize the vaccine.

Vaccine Schedule, Efficacy, and Costs

For the purposes of the calculations in this report, it was estimated that this vaccine would cost $100 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

RESULTS

If a vaccine program for HPV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 180,000. Using committee assumptions of less than ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 48,000.

If a vaccine program for HPV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $530 million. Using committee assumptions of less than ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $140 million.

If a vaccine program for HPV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $1.2 billion. Using committee assumptions of less than ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $435 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for a HPV vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $4,000. Using committee assumptions of less than ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $6,000.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

CDC, NCID. National Registry Established for Pediatric Recurrent Respiratory Papillomatosis. URL http://www.cdc.gov/ncidod/focus/vol6no2/dvrd.htm (accessed September 26, 1997).


Institute of Medicine. The Hidden Epidemic: Confronting Sexually Transmitted Diseases. Eng TR, Butler WT (eds.). Washington, DC: National Academy Press, 1997.


Miller BA, Kolonel LN, Bernstein L, et al. (eds). Racial/Ethnic Patterns of Cancer in the United States 1988–1992, National Cancer Institute. NIH Pub. No. 96–4104. Bethesda, MD, 1996.


Stoeckle MY. Human Herpesvirus 6 and Human Herpesvirus 7. In: Principles and Practice of Infectious Diseases. GL Mandell,, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1377–1400.

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

U.S. Bureau of the Census. Statistical Abstract of the U.S.: 1995 (115th edition). Washington, D.C. 1995.


Ventura SJ, Martin JA, Mathews TJ, et al. Advance Report of Final Natality statistics, 1994. Monthly Vital Statistics Report 1996; 44.

Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
This page in the original is blank.
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 213
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 214
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 215
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 216
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 217
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 218
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 219
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 220
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 221
Suggested Citation:"Appendix 11: Human Paillomavirus." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 222
Next: Appendix 12: Influenza A and B »
Vaccines for the 21st Century: A Tool for Decisionmaking Get This Book
×
Buy Hardback | $72.95 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

  • Lessons to be learned from the polio experience.
  • Scientific advances that set the stage for new vaccines.
  • Factors that affect how vaccines are used in the population.
  • Value judgments and ethical questions raised by comparison of health needs and benefits.

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!